Research powered investment banking
Home
Research
Companies
Find Alpha
Themes
Top Picks
Premium
Transactions
Events
Redeye
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Members network
Community
sign in
Home
research
Companies
Find Alpha
Themes
Top Picks
Transactions
Events
redeye
About
At a Glance
Our Culture
Investor Services
Corporate Broking
Certified Adviser
Corporate Finance
Newsroom
The Team
Careers
FAQ
Governance
Community
Company overview

NeuroVive: Secured Financing

Redeye Research Note timeStamp 2020/05/14

NeuroVive has raised SEK 67m through the preferential rights issue, subscribed to 90%. With this, the company has secured financing until the middle of 2021.

The rights issue was successfully completed, adding 83.7 million new shares to a total of 269.6 million. 26.2% of the issue was subscribed for by using the subscription rights and a high percentage, 63.5%, was subscribed for by the guarantors. This might make investors uncertain whether there will be a large sell-off. This has not been the case so far and we think this is because the agreement with the potential new long-term investor Hadean Ventures has boosted the confidence in the company and in the stock.

Hadean Ventures will invest up to SEK 20m in the company to a price of max SEK 0.75. There are two conditions for this: 1. That the rights issue is subscribed and paid to 90% (fulfilled), and 2. That the volume weighted average price (VWAP) between June 1st and June 12th is not below SEK 0.70. If this price falls below SEK 0.70, the investors can decide to pay on their own discretion SEK 0.70 per share.

We believe that both investors in the stock and guarantors might be waiting to see the outcome of the directed share issue and this is limiting the expected sell-off.

The improved financial position for NeuroVive also means that it can move its compounds further through clinical trials and thus increase the valuation of the company before a potential new capital raising.

Gergana Almquist

Gergana Almquist

Equity Analyst

Tagged companies
  • Office
  • Mäster Samuelsgatan 42, 10th floor
  • Box 7141, 103 87
  • Stockholm, Sweden
  • info@redeye.se
  • +46 (0)8 545 013 30
  • Services
  • Home
  • Research
  • Transactions
  • Events
  • Redeye
  • Community
  • Members Home
  • Premium
  • Legal
  • Terms and conditions (Swedish)
  • Terms of membership (Swedish)
  • Terms and conditions - Advisory (Swedish)
  • Terms and conditions - Advisory (English)
  • Integrity Policy (Swedish)
  • Disclaimer (Swedish)
  • Governance
  • Follow
  • Twitter
  • Facebook
  • LinkedIn
  • Redeye
  • At a Glance
  • Our Culture
  • Investor Services
  • Corporate Broking
  • Corporate Finance
  • Newsroom
  • The Team
  • Careers
  • FAQ

© All rights reserved. Redeye AB is authorised and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. 2021

You need to be a Redeye member to access this content

Become a member to:

  • Access all our extensive research on 100+ Nordic Tech and Life Science companies
  • Make smarter investment decisions with the guidance of our experienced analysts
  • Receive exciting offers to participate in IPO’s and other transactions

    By clicking "Sign up" you indicate that you read and agree to our Terms & Conditions

    I already have an account and want to sign in